JBIO Stock Summary and Trading Ideas (Jade Biosciences | NASDAQ:JBIO)

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Jade Biosciences trades on the NASDAQ stock market under the symbol JBIO.

As of August 28, 2026, JBIO stock price declined to $20.84 with 342,271 million shares trading.

JBIO has a beta of 1.70, meaning it tends to be more sensitive to market movements. JBIO has a correlation of 0.09 to the broad based SPY ETF.

JBIO has a market cap of $1.33 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that JBIO belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

JBIO has outperformed the market in the last year with a return of +157.9%, while the SPY ETF gained +19.7%. However, in the most recent history, JBIO shares have underperformed the stock market with its stock returning 0.0% in the last 3 month period and -15.7% for the last 2 week period, while SPY has returned +2.2% and -0.9%, respectively.

JBIO support price is $20.38 and resistance is $22.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JBIO shares will trade within this expected range on the day.